{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:35:08Z","timestamp":1780637708427,"version":"3.54.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prognosis of metastatic melanoma is very poor, due to the development of drug resistance. Cancer stem cells (CSCs) may play a crucial role in this mechanism, contributing to disease relapse. We first characterized CSCs in melanoma cell lines. We observed that A375 (but not BLM) cells are able to form melanospheres and show CSCs traits: expression of the pluripotency markers SOX2 and KLF4, higher invasiveness and tumor formation capability <jats:italic>in vivo<\/jats:italic> with respect to parental adherent cells. We also showed that a subpopulation of autofluorescent cells expressing the ABCG2 stem cell marker is present in the A375 spheroid culture. Based on these data, we investigated whether \u03b4-TT might target melanoma CSCs. We demonstrated that melanoma cells escaping the antitumor activity of \u03b4-TT are completely devoid of the ability to form melanospheres. In contrast, cells that escaped vemurafenib treatment show a higher ability to form melanospheres than control cells. \u03b4-TT also induced disaggregation of A375 melanospheres and reduced the spheroidogenic ability of sphere-derived cells, reducing the expression of the ABCG2 marker. These data demonstrate that \u03b4-TT exerts its antitumor activity by targeting the CSC subpopulation of A375 melanoma cells and might represent a novel chemopreventive\/therapeutic strategy against melanoma.<\/jats:p>","DOI":"10.1038\/s41598-017-19057-4","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T10:46:23Z","timestamp":1515408383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Targeting melanoma stem cells with the Vitamin E derivative \u03b4-tocotrienol"],"prefix":"10.1038","volume":"8","author":[{"given":"Monica","family":"Marzagalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Manuela","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Messi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Montagnani","family":"Marelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Bani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giangiacomo","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7028-3008","authenticated-orcid":false,"given":"Patrizia","family":"Limonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"19057_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7\u201330 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"19057_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-017-0458-3","volume":"10","author":"T Achkar","year":"2017","unstructured":"Achkar, T. & Tarhini, A. A. The use of immunotherapy in the treatment of melanoma. J Hematol. Oncol. 10, 88 (2017).","journal-title":"J Hematol. Oncol."},{"key":"19057_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4081\/oncol.2017.326","volume":"11","author":"BS Kalal","year":"2017","unstructured":"Kalal, B. S., Upadhya, D. & Pai, V. R. Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol. Rev. 11, 326 (2017).","journal-title":"Oncol. Rev."},{"key":"19057_CR4","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt, K., Platz, A., Kanter, L., Ringborg, U. & Hansson, J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9, 6483\u20136488 (2003).","journal-title":"Clin. Cancer Res."},{"key":"19057_CR5","doi-asserted-by":"crossref","first-page":"32258","DOI":"10.18632\/oncotarget.15632","volume":"8","author":"M Liu","year":"2017","unstructured":"Liu, M. et al. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget 8, 32258\u201332269 (2017).","journal-title":"Oncotarget"},{"key":"19057_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","volume":"28","author":"SB Peng","year":"2015","unstructured":"Peng, S. B. et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell 28, 384\u2013398 (2015).","journal-title":"Cancer Cell"},{"key":"19057_CR7","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1158\/0008-5472.CAN-11-1919","volume":"72","author":"M Moschetta","year":"2012","unstructured":"Moschetta, M. et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 72, 1814\u20131824 (2012).","journal-title":"Cancer Res."},{"key":"19057_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0571-0","volume":"14","author":"JM Redman","year":"2016","unstructured":"Redman, J. M., Gibney, G. T. & Atkins, M. B. Advances in immunotherapy for melanoma. BMC Med. 14, 20 (2016).","journal-title":"BMC Med."},{"key":"19057_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","volume":"43","author":"C Franklin","year":"2017","unstructured":"Franklin, C., Livingstone, E., Roesch, A., Schilling, B. & Schadendorf, D. Immunotherapy in melanoma: Recent advances and future directions. Eur. J. Surg. Oncol. 43, 604\u2013611 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"key":"19057_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/PPO.0000000000000182","volume":"22","author":"PA Prieto","year":"2016","unstructured":"Prieto, P. A., Reuben, A., Cooper, Z. A. & Wargo, J. A. Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J. 22, 138\u2013146 (2016).","journal-title":"Cancer J."},{"key":"19057_CR11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/jcp.25759","volume":"232","author":"MR Abbaszadegan","year":"2017","unstructured":"Abbaszadegan, M. R. et al. Isolation, identification, and characterization of cancer stem cells: A review. J. Cell. Physiol. 232, 2008\u20132018 (2017).","journal-title":"J. Cell. Physiol."},{"key":"19057_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5483\/BMBRep.2017.50.3.222","volume":"50","author":"K Eun","year":"2017","unstructured":"Eun, K., Ham, S. W. & Kim, H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep. 50, 117\u2013125 (2017).","journal-title":"BMB Rep."},{"key":"19057_CR13","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","volume":"66","author":"MF Clarke","year":"2006","unstructured":"Clarke, M. F. et al. Cancer stem cells\u2013perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339\u20139344 (2006).","journal-title":"Cancer Res."},{"key":"19057_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1574888X11666160607211436","volume":"12","author":"RP Nagare","year":"2017","unstructured":"Nagare, R. P., Sneha, S., Priya, S. K. & Ganesan, T. S. Cancer Stem Cells - Are Surface Markers Alone Sufficient? Curr. Stem Cell Res. Ther. 12, 37\u201344 (2017).","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"19057_CR15","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-15-2377","volume":"76","author":"SE Boyle","year":"2016","unstructured":"Boyle, S. E. et al. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Res. 76, 3965\u20133977 (2016).","journal-title":"Cancer Res."},{"key":"19057_CR16","doi-asserted-by":"publisher","unstructured":"Brinckerhoff, C. E. Cancer Stem Cells (CSCs) in melanoma: There\u2019s smoke, but is there fire? J. Cell. Physiol, https:\/\/doi.org\/10.1002\/jcp.25796 (2017).","DOI":"10.1002\/jcp.25796"},{"key":"19057_CR17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nmeth.3112","volume":"11","author":"I Miranda-Lorenzo","year":"2014","unstructured":"Miranda-Lorenzo, I. et al. Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. Nat Methods 11, 1161\u20131169 (2014).","journal-title":"Nat Methods"},{"key":"19057_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semcancer.2017.03.003","volume":"44","author":"A Agliano","year":"2017","unstructured":"Agliano, A., Calvo, A. & Box, C. The challenge of targeting cancer stem cells to halt metastasis. Semin. Cancer Biol. 44, 25\u201342 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"19057_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/stem.2579","volume":"35","author":"M Ahmed","year":"2017","unstructured":"Ahmed, M., Chaudhari, K., Babaei-Jadidi, R., Dekker, L. V. & Shams Nateri, A. Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells. Stem Cells 35, 839\u2013850 (2017).","journal-title":"Stem Cells"},{"key":"19057_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0578-3","volume":"16","author":"D Kumar","year":"2017","unstructured":"Kumar, D., Gorain, M., Kundu, G. & Kundu, G. C. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol. Cancer 16, 7 (2017).","journal-title":"Mol. Cancer"},{"key":"19057_CR21","doi-asserted-by":"publisher","unstructured":"Chen, Y. et al. (-)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt\/beta-Catenin Pathway. Nutrients 9, https:\/\/doi.org\/10.3390\/nu9060572 (2017).","DOI":"10.3390\/nu9060572"},{"key":"19057_CR22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.18632\/aging.101250","volume":"9","author":"JA McCubrey","year":"2017","unstructured":"McCubrey, J. A. et al. Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY) 9, 1477\u20131536 (2017).","journal-title":"Aging (Albany NY)"},{"key":"19057_CR23","doi-asserted-by":"publisher","unstructured":"Siddappa, G. et al. Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells. Mol. Carcinog, https:\/\/doi.org\/10.1002\/mc.22692 (2017).","DOI":"10.1002\/mc.22692"},{"key":"19057_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0571-x","volume":"16","author":"KS Siveen","year":"2017","unstructured":"Siveen, K. S., Uddin, S. & Mohammad, R. M. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol. Cancer 16, 13 (2017).","journal-title":"Mol. Cancer"},{"key":"19057_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1389202917666160803162309","volume":"18","author":"HF Torquato","year":"2017","unstructured":"Torquato, H. F., Goettert, M. I., Justo, G. Z. & Paredes-Gamero, E. J. Anti-Cancer Phytometabolites Targeting Cancer Stem Cells. Curr. Genomics 18, 156\u2013174 (2017).","journal-title":"Curr. Genomics"},{"key":"19057_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12154-014-0127-8","volume":"8","author":"H Ahsan","year":"2015","unstructured":"Ahsan, H., Ahad, A. & Siddiqui, W. A. A review of characterization of tocotrienols from plant oils and foods. J. Chem. Biol. 8, 45\u201359 (2015).","journal-title":"J. Chem. Biol."},{"key":"19057_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.maturitas.2016.11.003","volume":"95","author":"EN Georgousopoulou","year":"2017","unstructured":"Georgousopoulou, E. N., Panagiotakos, D. B., Mellor, D. D. & Naumovski, N. Tocotrienols, health and ageing: A systematic review. Maturitas 95, 55\u201360 (2017).","journal-title":"Maturitas"},{"key":"19057_CR28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s13197-017-2579-7","volume":"54","author":"D Raddatz-Mota","year":"2017","unstructured":"Raddatz-Mota, D. et al. Achiote (Bixa orellana L.): a natural source of pigment and vitamin E. J. Food Sci.Technol. 54, 1729\u20131741 (2017).","journal-title":"J. Food Sci.Technol."},{"key":"19057_CR29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/biof.1259","volume":"42","author":"L De Silva","year":"2016","unstructured":"De Silva, L., Chuah, L. H., Meganathan, P. & Fu, J. Y. Tocotrienol and cancer metastasis. Biofactors 42, 149\u2013162 (2016).","journal-title":"Biofactors"},{"key":"19057_CR30","doi-asserted-by":"publisher","unstructured":"Eitsuka, T., Tatewaki, N., Nishida, H., Nakagawa, K. & Miyazawa, T. Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. Int. J. Mol. Sci. 17, https:\/\/doi.org\/10.3390\/ijms17101605 (2016).","DOI":"10.3390\/ijms17101605"},{"key":"19057_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep30502","volume":"6","author":"M Montagnani Marelli","year":"2016","unstructured":"Montagnani Marelli, M. et al. Vitamin E delta-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells. Sci. Rep. 6, 30502 (2016).","journal-title":"Sci. Rep."},{"key":"19057_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","volume":"17","author":"LB Weiswald","year":"2015","unstructured":"Weiswald, L. B., Bellet, D. & Dangles-Marie, V. Spherical cancer models in tumor biology. Neoplasia 17, 1\u201315 (2015).","journal-title":"Neoplasia"},{"key":"19057_CR33","doi-asserted-by":"crossref","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370, doi:S0092-8674(00)81683-9 (2000).","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"19057_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2012.03.017","volume":"338","author":"CA La Porta","year":"2013","unstructured":"La Porta, C. A. & Zapperi, S. Human breast and melanoma cancer stem cells biomarkers. Cancer Lett. 338, 69\u201373 (2013).","journal-title":"Cancer Lett."},{"key":"19057_CR35","first-page":"22","volume":"4","author":"C Pincelli","year":"2017","unstructured":"Pincelli, C. p75 Neurotrophin Receptor in the Skin: Beyond Its Neurotrophic Function. Front. Med. (Lausanne) 4, 22 (2017).","journal-title":"Front. Med. (Lausanne)"},{"key":"19057_CR36","doi-asserted-by":"publisher","unstructured":"Speigl, L., Janssen, N., Weide, B., Pawelec, G. & Shipp, C. Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7\/8 in metastatic melanoma. Br. J. Dermatol, https:\/\/doi.org\/10.1111\/bjd.15194 (2016).","DOI":"10.1111\/bjd.15194"},{"key":"19057_CR37","doi-asserted-by":"publisher","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol, https:\/\/doi.org\/10.1038\/nrclinonc.2017.44 (2017).","DOI":"10.1038\/nrclinonc.2017.44"},{"key":"19057_CR38","doi-asserted-by":"publisher","unstructured":"Keller, H. R., Zhang, X., Li, L., Schaider, H. & Wells, J. W. Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget, https:\/\/doi.org\/10.18632\/oncotarget.18523 (2017).","DOI":"10.18632\/oncotarget.18523"},{"key":"19057_CR39","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/cncr.30435","volume":"123","author":"SY Lim","year":"2017","unstructured":"Lim, S. Y., Menzies, A. M. & Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 123, 2118\u20132129 (2017).","journal-title":"Cancer"},{"key":"19057_CR40","doi-asserted-by":"publisher","unstructured":"Obaid, N. M., Bedard, K. & Huang, W. Y. Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. Int. J. Mol. Sci. 18, https:\/\/doi.org\/10.3390\/ijms18030585 (2017).","DOI":"10.3390\/ijms18030585"},{"key":"19057_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.soc.2017.01.007","volume":"26","author":"KA Ahmed","year":"2017","unstructured":"Ahmed, K. A., Kim, S. & Harrison, L. B. Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. Surg. Oncol. Clin. N. Am. 26, 515\u2013529 (2017).","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"19057_CR42","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne, E. H. & Fisher, D. E. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 123, 2143\u20132153 (2017).","journal-title":"Cancer"},{"key":"19057_CR43","doi-asserted-by":"publisher","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol, https:\/\/doi.org\/10.1038\/nrclinonc.2017.43 (2017).","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"19057_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. & Smyth, M. J. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat. Rev. 52, 71\u201381 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"19057_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2017.03.012","volume":"120","author":"RF Sweis","year":"2017","unstructured":"Sweis, R. F. & Luke, J. J. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol. Res. 120, 1\u20139 (2017).","journal-title":"Pharmacol. Res."},{"key":"19057_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","volume":"46","author":"Q Wang","year":"2017","unstructured":"Wang, Q. & Wu, X. Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment. Int. Immunopharmacol. 46, 210\u2013219 (2017).","journal-title":"Int. Immunopharmacol."},{"key":"19057_CR47","first-page":"6146595","volume":"2016","author":"A Malik","year":"2016","unstructured":"Malik, A. et al. Role of Natural Radiosensitizers and Cancer Cell Radioresistance: An Update. Anal. Cell. Pathol. (Amst) 2016, 6146595 (2016).","journal-title":"Anal. Cell. Pathol. (Amst)"},{"key":"19057_CR48","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2147\/IJN.S130753","volume":"12","author":"B Yu","year":"2017","unstructured":"Yu, B. et al. Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells. Int. J. Nanomedicine 12, 2553\u20132567 (2017).","journal-title":"Int. J. Nanomedicine"},{"key":"19057_CR49","doi-asserted-by":"publisher","unstructured":"Parmiani, G. Melanoma Cancer Stem Cells: Markers and Functions. Cancers (Basel) 8, https:\/\/doi.org\/10.3390\/cancers8030034 (2016).","DOI":"10.3390\/cancers8030034"},{"key":"19057_CR50","first-page":"1291","volume":"31","author":"AA Alamodi","year":"2016","unstructured":"Alamodi, A. A. et al. Cancer stem cell as therapeutic target for melanoma treatment. Histol. Histopathol. 31, 1291\u20131301 (2016).","journal-title":"Histol. Histopathol."},{"key":"19057_CR51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21037\/atm.2016.06.07","volume":"4","author":"JL Manzano","year":"2016","unstructured":"Manzano, J. L. et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann. Transl. Med. 4, 237 (2016).","journal-title":"Ann. Transl. Med."},{"key":"19057_CR52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2183\/pjab.93.009","volume":"93","author":"H Colvin","year":"2017","unstructured":"Colvin, H. & Mori, M. Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 93, 146\u2013154 (2017).","journal-title":"Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci."},{"key":"19057_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00280-016-3048-0","volume":"78","author":"A Mahipal","year":"2016","unstructured":"Mahipal, A. et al. Pharmacokinetics and safety of vitamin E delta-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemother. Pharmacol. 78, 157\u2013165 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"19057_CR54","doi-asserted-by":"publisher","unstructured":"Qureshi, A. A., Khan, D. A., Silswal, N., Saleem, S. & Qureshi, N. Evaluation of Pharmacokinetics, and Bioavailability of Higher Doses of Tocotrienols in Healthy Fed Humans. J. Clin. Exp. Cardiolog. 7, https:\/\/doi.org\/10.4172\/2155-9880.1000434 (2016).","DOI":"10.4172\/2155-9880.1000434"},{"key":"19057_CR55","doi-asserted-by":"crossref","first-page":"31554","DOI":"10.18632\/oncotarget.15767","volume":"8","author":"K Husain","year":"2017","unstructured":"Husain, K. et al. delta-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Oncotarget 8, 31554\u201331567 (2017).","journal-title":"Oncotarget"},{"key":"19057_CR56","doi-asserted-by":"crossref","unstructured":"Subramaniam, D., Kaushik, G., Dandawate, P. & Anant, S. Targeting cancer stem cells for chemoprevention of pancreatic cancer. Curr. Med. Chem, doi:CMC-EPUB-81328 (2017).","DOI":"10.2174\/0929867324666170127095832"},{"key":"19057_CR57","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/ijc.25546","volume":"128","author":"SU Luk","year":"2011","unstructured":"Luk, S. U. et al. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer 128, 2182\u20132191 (2011).","journal-title":"Int. J. Cancer"},{"key":"19057_CR58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jmcb\/mjs042","volume":"5","author":"SO Lee","year":"2013","unstructured":"Lee, S. O. et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem\/progenitor vs. non-stem\/progenitor cells. J. Mol. Cell. Biol. 5, 14\u201326 (2013).","journal-title":"J. Mol. Cell. Biol."},{"key":"19057_CR59","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/bjc.2016.257","volume":"115","author":"S Prasad","year":"2016","unstructured":"Prasad, S., Gupta, S. C., Tyagi, A. K. & Aggarwal, B. B. gamma-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules. Br. J. Cancer 115, 814\u2013824 (2016).","journal-title":"Br. J. Cancer"},{"key":"19057_CR60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/mc.22291","volume":"55","author":"A Xiong","year":"2016","unstructured":"Xiong, A., Yu, W., Liu, Y., Sanders, B. G. & Kline, K. Elimination of ALDH+breast tumor initiating cells by docosahexanoic acid and\/or gamma tocotrienol through SHP-1 inhibition of Stat3 signaling. Mol. Carcinog. 55, 420\u2013430 (2016).","journal-title":"Mol. Carcinog."},{"key":"19057_CR61","doi-asserted-by":"publisher","first-page":"2048731","DOI":"10.1155\/2016\/2048731","volume":"2016","author":"LY Pang","year":"2016","unstructured":"Pang, L. Y., Hurst, E. A. & Argyle, D. J. Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy. Stem Cells Int. 2016, 2048731 (2016).","journal-title":"Stem Cells Int."},{"key":"19057_CR62","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cell.2009.01.015","volume":"136","author":"W Goessling","year":"2009","unstructured":"Goessling, W. et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136\u20131147 (2009).","journal-title":"Cell"},{"key":"19057_CR63","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-017-0585-2","volume":"36","author":"P Zhou","year":"2017","unstructured":"Zhou, P. et al. Combination therapy of PKCzeta and COX-2 inhibitors synergistically suppress melanoma metastasis. J. Exp. Clin. Cancer Res. 36, 115 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"19057_CR64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2016.03.018","volume":"95","author":"Y Jang","year":"2016","unstructured":"Jang, Y., Park, N. Y., Rostgaard-Hansen, A. L., Huang, J. & Jiang, Q. Vitamin E metabolite 13\u2032-carboxychromanols inhibit pro-inflammatory enzymes, induce apoptosis and autophagy in human cancer cells by modulating sphingolipids and suppress colon tumor development in mice. Free Radic. Biol. Med. 95, 190\u2013199 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"19057_CR65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.canlet.2012.10.003","volume":"328","author":"A Gopalan","year":"2013","unstructured":"Gopalan, A., Yu, W., Sanders, B. G. & Kline, K. Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Cancer Lett. 328, 285\u2013296 (2013).","journal-title":"Cancer Lett."},{"key":"19057_CR66","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF01753729","volume":"9","author":"GN Van Muijen","year":"1991","unstructured":"Van Muijen, G. N. et al. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin. Exp. Metastasis 9, 259\u2013272 (1991).","journal-title":"Clin. Exp. Metastasis"},{"key":"19057_CR67","doi-asserted-by":"publisher","unstructured":"Beretta, G. et al. Semi-preparative HPLC purification of delta-tocotrienol (delta-T3) from Elaeis guineensis Jacq. and Bixa orellana L. and evaluation of its in vitro anticancer activity in human A375 melanoma cells. Nat. Prod. Res, https:\/\/doi.org\/10.1080\/14786419.2017.1320793 (2017).","DOI":"10.1080\/14786419.2017.1320793"},{"key":"19057_CR68","doi-asserted-by":"publisher","first-page":"e0134396","DOI":"10.1371\/journal.pone.0134396","volume":"10","author":"M Marzagalli","year":"2015","unstructured":"Marzagalli, M., Casati, L., Moretti, R. M., Montagnani Marelli, M. & Limonta, P. Estrogen Receptor beta Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS One 10, e0134396 (2015).","journal-title":"PLoS One"},{"key":"19057_CR69","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555\u20131577 (2010).","journal-title":"Br. J. Cancer"},{"key":"19057_CR70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10456-017-9549-6","volume":"20","author":"M Bani","year":"2017","unstructured":"Bani, M., Decio, A., Giavazzi, R. & Ghilardi, C. Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis 20, 233\u2013241 (2017).","journal-title":"Angiogenesis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19057-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:47:09Z","timestamp":1671583629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19057-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19057"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-19057-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"9 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"587"}}